International Stem Cell Corporation Completes Important Study in Parkinson's Disease Program

The recently completed IND-enabling study transplanting rodents with human neural stem cells, derived from ISCO's proprietary parthenogenetic stem cell platform, showed that the cells are well tolerated even at high doses up to the equivalent of 2.2 billion cells in humans.

http://ift.tt/UgCT5P